+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatitis D - Market Insight, Epidemiology and Market Forecast - 2030

  • ID: 4520740
  • Drug Pipelines
  • January 2021
  • Region: Global
  • 153 pages
  • DelveInsight

FEATURED COMPANIES

  • Eiger Biopharmaceuticals
This ‘Hepatitis D Virus (HDV) - Market Insights, Epidemiology, and Market Forecast - 2030’ report delivers an in-depth understanding of the HDV, historical and forecasted epidemiology as well as the HDV market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The HDV market report provides current treatment practices, emerging drugs, HDV market share of the individual therapies, current and forecasted HDV market size from 2017 to 2030 segmented by seven major markets. The Report also covers current HDV treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Hepatitis D Virus (HDV): Disease Understanding and Treatment Algorithm

Hepatitis D Virus (HDV) Overview

Hepatitis D is caused by infection with the hepatitis D virus (HDV), also known as Delta Virus, and is considered to be the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma. HDV occurs only in individuals positive for the hepatitis B virus (HBV) surface antigen (HBsAg) as HDV is a defective RNA viroid that requires HBsAg for transmission. HDV shares common modes of transmission as HBV and can be acquired either as coinfection or superinfection to HBV. Simultaneous infection (i.e. co-infection) with HBV and HDV can lead to a mild-to-severe or even fulminant hepatitis, whereas the super-infection of HDV on chronic hepatitis B accelerates progression to a more severe disease in all ages and in 70‒90% of people.

The mode of transmission is commonly through contact with blood or other body fluids, including sexual contact with an infected partner, injection-drug use that involves sharing needles, syringes, or drug-preparation equipment and needle sticks or exposures to sharp instruments. Vertical transmission from mother to child is rare. Infection with HDV can worsen symptoms of HBV infection or hepatitis B-associated liver disease. It can cause symptoms to occur in people who previously did not have symptoms of HBV infection. The symptoms of HDV infection are similar to those experienced with HBV infection and can include yellowing of the skin and eyes (jaundice), gastrointestinal (GI) issues such as nausea, vomiting, and abdominal pain, tiredness, loss of appetite, dark-colored urine, joint pain, etc.

The severity of hepatitis D is influenced by the HDV genotype. Although infection with multiple genotypes may occur in patients at high risk of repeated exposure such as injecting drug users, a single genotype usually predominates with >10% of the viral load being represented by the minor strain. There are at least 8 genotypes (genetic variants) of HDV based on 14-38% sequence variation. These genotypes are associated with different long-term outcomes. Genotype 1 chronic HDV super-infection usually leads to a rapid progression to cirrhosis. Genotypes 2 and 4 cause a milder disease over a longer time course whereas genotype 3 is associated with advanced necroinflammatory.

Hepatitis D Virus (HDV) Diagnosis

The diagnosis of HDV is based on the medical history, a physical exam, and blood tests of the patients. HDV infection is diagnosed by high levels of Immunoglobulin G (IgG) and Immunoglobulin M (IgM) anti-HDV. As cases of hepatitis D are not clinically distinguishable from other types of acute viral hepatitis, diagnosis can be confirmed only by testing for the presence of antibodies against HDV and/or HDV RNA. The doctor may recommend tests to find out whether the patient has liver damage or how much liver damage or to rule out other causes of liver disease. These tests may include elastography, a special ultrasound that measures the stiffness of the liver, liver enzyme function tests, and a liver biopsy, wherein a doctor uses a needle to take a small piece of tissue from the liver.

Hepatitis D Virus (HDV) Treatment

Treatment options for HDV are limited and optimal treatment is not known. There are no known treatments for acute HDV. The goal of treatment is to suppress HDV replication which is shown by the inability to detect HDV RNA in serum and HDAg in the liver. Pegylated interferon-alpha has shown some efficacy, but the sustained virologic response rate (a measure of viral clearance) is low. The pegylated form of IFN alpha is recommended to be the preferred agent as per expert guidelines. Hepcludex is the first therapy approved in Europe and has been granted Conditional Marketing Authorization (CMA) for the treatment of HDV. It works as an entry inhibitor that is, it prevents HDV cells and the HBV cells upon which HDV is prevented, from entering healthy liver cells. Liver transplantation is the only treatment option for patients with end-stage liver cirrhosis resulting from HDV.

HDV Epidemiology

The HDV epidemiology division provides insights about the historical and current HDV patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2017, the Total Diagnosed Prevalent cases of HDV was 204,976 in the 7MM which are expected to grow during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted HDV epidemiology [segmented as Total Diagnosed Prevalent Cases of HDV, Gender-specific Diagnosed Prevalent Cases of HDV, Age-specific Diagnosed Prevalent Cases of HDV, Diagnosed Prevalent Cases of HDV by Impact on Liver and Treated cases of HDV] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- HDV Epidemiology

Estimates show that the highest cases of HDV in the 7MM were in the United States, followed by Japan, Germany, Italy, Spain, the United Kingdom, and France in 2017.
  • In the United States, the total diagnosed prevalent cases of HDV was 112,673 cases in the year 2017 which are expected to grow during the study period, i.e., 2017-2030.
  • In the year 2017, the total diagnosed prevalent cases of HDV were 64,845 cases in EU-5 which are expected to grow during the study period, i.e., 2017-2030.
  • In Japan, the total diagnosed prevalent cases of HDV was 27,458 cases in the year 2017 which are expected to grow during the study period, i.e., 2017-2030.
HDV Drug Chapters

The drug chapter segment of the HDV report encloses the detailed analysis of HDV marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the HDV clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

HDV Emerging Drugs

Hepcludex/Bulevirtide (MYR Pharmaceuticals/Hepatera)

Hepcludex (Bulevirtide) is a novel drug candidate for the treatment of chronic HDV. Its antiviral mode of action relies on specific binding and blockage of the hepatocyte surface protein NTCP. Bulevirtide-mediated inhibition of NTCP prevents entry of HBV and HDV into the cell, hence infection of hepatocytes is prevented. It was previously known as Myrcludex B.

In August 2020, the European Commission (EC) granted the Conditional Marketing Authorization (CMA) for Hepcludex. It has been approved as the first treatment option for adult patients with chronic HDV infection and compensated liver disease in Europe. In September 2020, MYR Pharmaceuticals announced that Hepcludex (bulevirtide) has been successfully launched in Germany, France, and Austria.

Lonafarnib (Eiger Biopharmaceuticals)

Lonafarnib is in development as a first-in-class prenylation inhibitor, boosted with ritonavir, for the treatment of HDV infection. Lonafarnib is a well-characterized, orally active inhibitor of farnesyl transferase, an enzyme involved in the modification of proteins through a process called prenylation, a vital process in the life cycle of HDV.

In January 2014, an orphan designation (EU/3/13/1225) was granted by the European Commission to lonafarnib for the treatment of HDV infection. Then in December 2018, the European Medicines Agency (EMA) granted PRIME (PRIority MEdicines) designation for lonafarnib. Also, in 2018, the US FDA granted Breakthrough Therapy designation for lonafarnib for the treatment of HDV infection.

Peginterferon Lambda (Eiger Biopharmaceuticals)

Peginterferon Lambda is a well-characterized, late-stage, first in class, type III interferon (IFN) being developed as better-tolerated interferon. Lambda stimulates immune responses that are critical for the development of host protection during viral infections. Eiger Pharmaceuticals is developing it as both a monotherapy and in combination therapy with Lonafarnib + Ritonavir

In August 2019, the US FDA granted Breakthrough Therapy Designation for peginterferon lambda (Lambda) for the treatment of HDV infection. Previously, in September 2017, the US FDA granted an orphan designation for pegylated interferon lambda 1a as a potential treatment for chronic HDV infection. Also, in July 2017, the US FDA granted Fast Track designation for pegylated interferon lambda 1a (Lambda).

JNJ-73763989 (Janssen Biopharmaceuticals)

JNJ-73763989 also known as JNJ-3989 is a liver-targeted antiviral therapeutic for subcutaneous injection via ribonucleic acid interference mechanism. It is designed to silence all HBV gene products and intervenes upstream of the reverse transcription process. The trials are also being conducted by the company for JNJ-73763989 to treat chronic HBV infection.

Note: Detailed emerging therapies assessment will be provided in the final report.

HDV Market Outlook

Currently, treatment strategies for HDV mainly include interferon (IFN)-based therapy. Antiviral therapy with interferon alfa can be considered in patients with chronic hepatitis D virus (HDV) infection. The treatment course is usually at least 1 year. PegIFNa is the only available drug that has been proven to have some antiviral efficacy against chronic HDV infection. Interferons may be effective at a very early stage of infection when HDV is entering hepatocytes rather than at the stage of established intracellular hepatocyte HDV infection. Recently, Hepcludex has been approved as the first treatment option for adult patients with chronic HDV infection and compensated liver disease in Europe.

At present, some companies have indulged themselves to initiate clinical trials that investigate new treatment options. Key players such as Eiger Biopharmaceuticals (Lonafarnib, Peginterferon Lambda-1A), Janssen Pharmaceuticals (JNJ-73763989), and several others are investigating their candidates for the management of HDV in the 7MM.

Key Findings

The HDV market size in the 7MM is expected to change during the study period 2017-2030. The therapeutic market of HDV in the seven major markets was USD 285.1 million in 2017 which is expected to increase during the study period (2017-2030). According to the estimates, the highest market size of HDV is found in the United States followed by Japan and Germany.

The United States Market Outlook

In 2017, the total market size of HDV therapies was USD 212.4 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of HDV therapies was USD 49.2 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of HDV therapies in Japan was USD 23.5 million in 2017 which is expected to increase in the study period (2017-2030).

HDV Pipeline Development Activities

The drugs which are in pipeline include:
  • Hepcludex/Bulevirtide (MYR Pharmaceuticals/Hepatera)
  • Lonafarnib (Eiger Biopharmaceuticals)
  • Peginterferon Lambda (Eiger Biopharmaceuticals)
  • JNJ-73763989 (Janssen Biopharmaceuticals)
Note: Detailed emerging therapies assessment will be provided in the final report.

HDV Drugs Uptake

Among emerging therapies, Lonafarnib + Ritonavir ± Peginterferon-Alfa combo from Eiger BioPharmaceuticals expected to garner the highest patient share owing to expected early mover advantage, patient-friendly dosing (i.e. oral), and promising efficacy signals in early-stage trials.

Access and Reimbursement Scenario in HDV Therapies

Currently, no vaccine is available for hepatitis D. Hepatitis B vaccine is the single most crucial tool to prevent HBV-HDV coinfection since persons immune from HBV infection cannot become infected with HDV. In the UK, children and adults in high-risk groups are offered the vaccine. All babies in the UK born on or after 1 August 2017 are given three doses of hepatitis B-containing vaccine as part of the NHS routine vaccination schedule. These doses are given at 8, 12, and 16 weeks of age. Babies born to mothers with hepatitis B infection will be given 6 doses of hepatitis B-containing vaccine to ensure long-lasting protection.

Note: HTA assessment will be provided in the final report.

KOL Views

To keep up with current market trends,the publisher takes KOLs and SME’s opinion working in the HDV domain through primary research to fill the data gaps and validate the secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or HDV market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the HDV Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of HDV, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the HDV epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for HDV is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the HDV market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global HDV market.
Report Highlights
  • In the coming years, the HDV market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence HDV R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for HDV. The launch of emerging therapies will significantly impact the HDV market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for HDV.
  • the in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
HDV Report Insights
  • Patient Population
  • Therapeutic Approaches
  • HDV Pipeline Analysis
  • HDV Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
HDV Report Key Strengths
  • 11 Years Forecast
  • 7MM Coverage
  • HDV Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
HDV Report Assessment
  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What was the HDV Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the HDV total market size as well as market size by therapies across the 7MM during the study period (2017-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest HDV market size during the study period (2017-2030)?
  • At what CAGR, the HDV market is expected to grow in the 7MM during the study period (2017-2030)?
  • What would be the HDV market outlook across the 7MM during the study period (2017-2030)?
  • What would be the HDV market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
  • HDV patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration, and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the HDV market?
Epidemiology Insights:
  • What are the disease risk, burdens, and unmet needs of the HDV?
  • What is the historical HDV patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What would be the forecasted patient pool of HDV in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to HDV?
  • Out of all the 7MM countries, which country would have the highest prevalent population of HDV during the study period (2017-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of HDV?
Current Treatment Scenario and Emerging Therapies:
  • What are the current options for the treatment of HDV?
  • What are the current treatment guidelines for the treatment of HDV in the US, Europe, and Japan?
  • How many companies are developing therapies for the treatment of HDV?
  • How many therapies are developed by each company for the treatment of HDV?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of HDV?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HDV therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for HDV and their status?
  • What are the key designations that have been granted for the emerging therapies for HDV?
  • What is the global historical and forecasted market of HDV?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the HDV market.
  • To understand the future market competition in the HDV market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for HDV in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the HDV market.
  • To understand the future market competition in the HDV market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Eiger Biopharmaceuticals
1. Key Insights

2. Executive Summary of the Hepatitis D Virus (HDV)

3. SWOT Analysis of Hepatitis D Virus (HDV)

4. Hepatitis D Virus (HDV): Market Share (%) Distribution Overview at a Glance: By Country

5. Epidemiology and Market Methodology

6. Hepatitis Delta Virus (HDV): Disease Background and Overview
6.1. Introduction
6.1.1. Signs and Symptoms of HDV
6.1.2. Risk Factors and Causes of HDV
6.1.3. Pathophysiology of HDV
6.1.4. Factors influencing HDV progression
6.1.5. Complications of HDV Infection

7. Diagnosis of Hepatitis D Infection
7.1. Physical exam
7.2. Blood Tests
7.2.1. Antibodies to HDV
7.2.2. HDV RNA
7.2.3. HD-Antigen
7.2.4. IgM Antibody to the Hepatitis B Core Antigen (IgM Anti-HBc)
7.2.5. HDV genotyping
7.3. Imaging Tests
7.4. Liver Biopsy
7.5. Differential diagnosis for HDV

8. Prevention of HDV

9. Epidemiology and Patient Population
9.1. Epidemiology Key Findings
9.2. Assumptions and Rationale: 7MM

10. Epidemiology Scenario: 7MM
10.1. Total Diagnosed Prevalent cases of HDV in the 7MM
10.2. Gender-specific Diagnosed Prevalent Cases of HDV in the 7MM
10.3. Age-specific Diagnosed Prevalent Cases of HDV in the 7MM
10.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in the 7MM
10.5. Treated cases of HDV in the 7MM

11. The United States Epidemiology
11.1. Total Diagnosed Prevalent cases of HDV in the United States
11.2. Gender-specific Diagnosed Prevalent Cases of HDV in the United States
11.3. Age-specific Diagnosed Prevalent Cases of HDV in the United States
11.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in the United States
11.5. Treated cases of HDV in the United States

12. EU-5 Epidemiology
12.1. Germany
12.1.1. Total Diagnosed Prevalent cases of HDV in Germany
12.1.2. Gender-specific Diagnosed Prevalent Cases of HDV in Germany
12.1.3. Age-specific Diagnosed Prevalent Cases of HDV in Germany
12.1.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Germany
12.1.5. Treated cases of HDV in Germany
12.2. France
12.2.1. Total Diagnosed Prevalent cases of HDV in France
12.2.2. Gender-specific Diagnosed Prevalent Cases of HDV in France
12.2.3. Age-specific Diagnosed Prevalent Cases of HDV in France
12.2.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in France
12.2.5. Treated cases of HDV in France
12.3. Italy
12.3.1. Total Diagnosed Prevalent cases of HDV in Italy
12.3.2. Gender-specific Diagnosed Prevalent Cases of HDV in Italy
12.3.3. Age-specific Diagnosed Prevalent Cases of HDV in Italy
12.3.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Italy
12.3.5. Treated cases of HDV in Italy
12.4. Spain
12.4.1. Total Diagnosed Prevalent cases of HDV in Spain
12.4.2. Gender-specific Diagnosed Prevalent Cases of HDV in Spain
12.4.3. Age-specific Diagnosed Prevalent Cases of HDV in Spain
12.4.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Spain
12.4.5. Treated cases of HDV in Spain
12.5. The United Kingdom
12.5.1. Total Diagnosed Prevalent cases of HDV in the United Kingdom
12.5.2. Gender-specific Diagnosed Prevalent Cases of HDV in the United Kingdom
12.5.3. Age-specific Diagnosed Prevalent Cases of HDV in the United Kingdom
12.5.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in the United Kingdom
12.5.5. Treated cases of HDV in the United Kingdom

13. Japan Epidemiology
13.1. Total Diagnosed Prevalent cases of HDV in Japan
13.2. Gender-specific Diagnosed Prevalent Cases of HDV in Japan
13.3. Age-specific Diagnosed Prevalent Cases of HDV in Japan
13.4. Diagnosed Prevalent Cases of HDV by Impact on Liver in Japan
13.5. Treated cases of HDV in Japan

14. Current Treatment Practices: HDV
14.1. Treatment Algorithm of HDV
14.2. Peg IFN α
14.3. Alternative Options
14.4. Liver transplantation

15. Guidelines of HDV
15.1. American Association for the Study of Liver Diseases (AASLD) Treatment Guidelines
15.2. European Association for the Study of the Liver (EASL) Guidelines

16. Unmet Needs

17. Patient Journey of HDV

18. Key Endpoints in HDV Clinical Trials

19. Emerging Therapies
19.1. Hepcludex (Bulevirtide): MYR Pharmaceuticals/Hepatera
19.1.1. Regulatory Milestones
19.1.2. Other Developmental Activities
19.1.3. Pivotal Clinical Trial
19.1.4. Ongoing Current Pipeline Activity
19.2. Lonafarnib: Eiger Biopharmaceuticals
19.2.1. Product Description
19.2.2. Other Developmental Activities
19.2.3. Clinical Development
19.2.4. Safety and Efficacy
19.3. Peginterferon Lambda: Eiger Biopharmaceuticals
19.3.1. Product Description
19.3.2. Other Developmental Activities
19.3.3. Clinical Development
19.3.4. Safety and Efficacy
19.4. JNJ-73763989 (JNJ-3989): Janssen Pharmaceuticals
19.4.1. Product Description
19.4.2. Clinical Development

20. Hepatitis D Virus (HDV): Seven Major Market Analysis
20.1. Key Findings
20.2. Market Outlook: 7MM

21. 7MM Market Size
21.1. Total Market Size of HDV in the 7MM
21.2. Total Market size of HDV by Therapies in the 7MM

22. United States Market Size
22.1. Total Market size of HDV in the United States

23. EU-5 Market Size
23.1. Germany Market Size
23.1.1. Total Market size of HDV in Germany
23.2. France Market Size
23.2.1. Total Market size of HDV in France
23.3. Italy Market Size
23.3.1. Total Market size of HDV in Italy
23.4. Spain Market Size
23.4.1. Total Market size of HDV in Spain
23.5. United Kingdom Market Size
23.5.1. Total Market size of HDV in the United Kingdom

24. Japan Market Size
24.1. Total Market size of HDV in Japan

25. Market Access and Reimbursement of HDV Therapies
25.1. NHS Recommendation about Vaccination programs
25.2. Reimbursement policy of Medicare
25.3. Expanded Access Policy

26. Market Drivers

27. Market Barriers

28. Appendix
28.1. Bibliography
28.2. Report Methodology

29. Publisher Capabilities

30. Disclaimer

31. About the Publisher

List of Tables
Table 1: Summary of the Hepatitis D Virus (HDV) Market, Epidemiology, and Key Events (2017-2030)
Table 2: Summary of diagnostic tests for the evaluation of patients with HDV infection
Table 3: Total Diagnosed Prevalent cases of HDV in the 7MM (2017-2030)
Table 4: Gender-specific Diagnosed Prevalent Cases of HDV in the 7MM (2017-2030)
Table 5: Age-specific Prevalent Cases of HDV in the 7MM (2017-2030)
Table 6: Diagnosed Prevalent Cases of HDV by Impact on Liver in the 7MM (2017-2030)
Table 7: Total Treated cases of HDV in the 7MM (2017-2030)
Table 8: Total Diagnosed Prevalent cases of HDV in the United States (2017-2030)
Table 9: Gender-specific Diagnosed Prevalent Cases of HDV in the United States (2017-2030)
Table 10: Age-specific Prevalent Cases of HDV in the United States (2017-2030)
Table 11: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United States (2017-2030)
Table 12:Total Treated cases of HDV in the United States (2017-2030)
Table 13: Total Diagnosed Prevalent cases of HDV in Germany (2017-2030)
Table 14: Gender-specific Diagnosed Prevalent Cases of HDV in Germany (2017-2030)
Table 15: Age-specific Prevalent Cases of HDV in Germany (2017-2030)
Table 16: Diagnosed Prevalent Cases of HDV by Impact on Liver in Germany (2017-2030)
Table 17: Total Treated cases of HDV in Germany (2017-2030)
Table 18: Total Diagnosed Prevalent cases of HDV in France (2017-2030)
Table 19: Gender-specific Diagnosed Prevalent Cases of HDV in France (2017-2030)
Table 20: Age-specific Prevalent Cases of HDV in France (2017-2030)
Table 21: Diagnosed Prevalent Cases of HDV by Impact on Liver in France (2017-2030)
Table 22: Total Treated cases of HDV in France (2017-2030)
Table 23: Total Diagnosed Prevalent cases of HDV in Italy (2017-2030)
Table 24: Gender-specific Diagnosed Prevalent Cases of HDV in Italy (2017-2030)
Table 25: Age-specific Prevalent Cases of HDV in Italy (2017-2030)
Table 26: Diagnosed Prevalent Cases of HDV by Impact on Liver in Italy (2017-2030)
Table 27: Total Treated cases of HDV in Italy (2017-2030)
Table 28: Total Diagnosed Prevalent cases of HDV in Spain (2017-2030)
Table 29: Gender-specific Diagnosed Prevalent Cases of HDV in Spain (2017-2030)
Table 30: Age-specific Prevalent Cases of HDV in Spain (2017-2030)
Table 31: Diagnosed Prevalent Cases of HDV by Impact on Liver in Spain (2017-2030)
Table 32: Total Treated cases of HDV in Spain (2017-2030)
Table 33: Total Diagnosed Prevalent cases of HDV in the United Kingdom (2017-2030)
Table 34: Gender-specific Diagnosed Prevalent Cases of HDV in the United Kingdom (2017-2030)
Table 35: Age-specific Prevalent Cases of HDV in the United Kingdom (2017-2030)
Table 36: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United Kingdom (2017-2030)
Table 37: Total Treated cases of HDV in the United Kingdom (2017-2030)
Table 38: Total Diagnosed Prevalent cases of HDV in Japan (2017-2030)
Table 39: Gender-specific Diagnosed Prevalent Cases of HDV in Japan (2017-2030)
Table 40: Age-specific Prevalent Cases of HDV in Japan (2017-2030)
Table 41: Diagnosed Prevalent Cases of HDV by Impact on Liver in Japan (2017-2030)
Table 42: Total Treated cases of HDV in Japan (2017-2030)
Table 43: Lonafarnib + Ritonavir, Clinical Trial Description, 2020
Table 44: Peginterferon lambda, Clinical Trial Description, 2020
Table 45 : JNJ-73763989, Clinical Trial Description, 2020
Table 46: 7MM Market Size of HDV, in USD Million (2017-2030)
Table 47: 7MM Market Size of HDV by Therapies, in USD Million (2017-2030)
Table 48: United States Market Size of HDV by Therapies, in USD Million (2017-2030)
Table 49: Germany Market Size of HDV by Therapies, in USD Million (2017-2030)
Table 50: France Market Size of HDV by Therapies, in USD Million (2017-2030)
Table 51: Italy Market Size of HDV by Therapies, in USD Million (2017-2030)
Table 52: Spain Market Size of HDV by Therapies, in USD Million (2017-2030)
Table 53: United Kingdom Market Size of HDV by Therapies, in USD Million (2017-2030)
Table 54: Japan Market Size of HDV by Therapies, in USD Million (2017-2030)

List of Figures
Figure 1: HDV SWOT Analysis
Figure 2: Epidemiology and Market Methodology
Figure 3: Progression of HDV Infection
Figure 4: Signs and symptoms of HDV Infection
Figure 5: HBV-HDV Coinfection
Figure 6: HBV-HDV Superinfection
Figure 7: Causes of HDV
Figure 8: Virion structure of HDV
Figure 9: Virus Replication Cycle
Figure 10: Complications of HDV Infection
Figure 11: Diagnostic Algorithm of HDV
Figure 12: Blood Test
Figure 13: Percutaneous liver biopsy
Figure 14: Prevention of HDV
Figure 15: Total Diagnosed Prevalent cases of HDV in the 7MM (2017-2030)
Figure 16: Gender-specific Diagnosed Prevalent Cases of HDV in the 7MM (2017-2030)
Figure 17: Age-specific Diagnosed Prevalent Cases of HDV in the 7MM (2017-2030)
Figure 18: Diagnosed Prevalent Cases of HDV by Impact on Liver in the 7MM (2017-2030)
Figure 19: Treated cases of HDV in the 7MM (2017-2030)
Figure 20: Total Diagnosed Prevalent cases of HDV in the United States (2017-2030)
Figure 21: Gender-specific Diagnosed Prevalent Cases of HDV in the United States (2017-2030)
Figure 22: Age-specific Diagnosed Prevalent Cases of HDV in the United States (2017-2030)
Figure 23: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United States (2017-2030)
Figure 24: Treated cases of HDV in the United States (2017-2030)
Figure 25: Total Diagnosed Prevalent cases of HDV in Germany (2017-2030)
Figure 26: Gender-specific Diagnosed Prevalent Cases of HDV in Germany (2017-2030)
Figure 27:Age-specific Diagnosed Prevalent Cases of HDV in Germany (2017-2030)
Figure 28: Diagnosed Prevalent Cases of HDV by Impact on Liver in Germany (2017-2030)
Figure 29: Treated cases of HDV in Germany (2017-2030)
Figure 30: Total Diagnosed Prevalent cases of HDV in France (2017-2030)
Figure 31: Gender-specific Diagnosed Prevalent Cases of HDV in France (2017-2030)
Figure 32:Age-specific Diagnosed Prevalent Cases of HDV in France (2017-2030)
Figure 33: Diagnosed Prevalent Cases of HDV by Impact on Liver in France (2017-2030)
Figure 34: Treated cases of HDV in France (2017-2030)
Figure 35: Total Diagnosed Prevalent cases of HDV in Italy (2017-2030)
Figure 36: Gender-specific Diagnosed Prevalent Cases of HDV in Italy (2017-2030)
Figure 37: Age-specific Diagnosed Prevalent Cases of HDV in Italy (2017-2030)
Figure 38: Diagnosed Prevalent Cases of HDV by Impact on Liver in Italy (2017-2030)
Figure 39: Treated cases of HDV in Italy (2017-2030)
Figure 40: Total Diagnosed Prevalent cases of HDV in Spain (2017-2030)
Figure 41: Gender-specific Diagnosed Prevalent Cases of HDV in Spain (2017-2030)
Figure 42: Age-specific Diagnosed Prevalent Cases of HDV in Spain (2017-2030)
Figure 43: Diagnosed Prevalent Cases of HDV by Impact on Liver in Spain (2017-2030)
Figure 44: Treated cases of HDV in Spain (2017-2030)
Figure 45: Total Diagnosed Prevalent cases of HDV in the United Kingdom (2017-2030)
Figure 46: Gender-specific Diagnosed Prevalent Cases of HDV in the United Kingdom (2017-2030)
Figure 47: Age-specific Diagnosed Prevalent Cases of HDV in the United Kingdom (2017-2030)
Figure 48: Diagnosed Prevalent Cases of HDV by Impact on Liver in the United Kingdom (2017-2030)
Figure 49: Treated cases of HDV in the United Kingdom (2017-2030)
Figure 50: Total Diagnosed Prevalent cases of HDV in Japan (2017-2030)
Figure 51: Gender-specific Diagnosed Prevalent Cases of HDV in Japan (2017-2030)
Figure 52: Age-specific Diagnosed Prevalent Cases of HDV in Japan (2017-2030)
Figure 53: Diagnosed Prevalent Cases of HDV by Impact on Liver in Japan (2017-2030)
Figure 54: Treated cases of HDV in Japan (2017-2030)
Figure 55: Treatment Algorithm of HDV
Figure 56: Treatment Algorithm of HDV
Figure 57: Unmet Needs for HDV
Figure 58: Mechanism of action
Figure 59: Mechanism of action of Lonafarnib
Figure 60: Mechanism of action of Peginterferon Lambda
Figure 61: Market Size of HDV in the 7MM, in USD Million (2017-2030)
Figure 62: Market Size of HDV in the 7MM by Therapies, in USD Million (2017-2030)
Figure 63: Market Size of HDV in the United States by Therapy, in USD Million (2017-2030)
Figure 64: Market Size of HDV in Germany by Therapies, in USD Million (2017-2030)
Figure 65: Market Size of HDV in France by therapies, in USD Million (2017-2030)
Figure 66: Market Size of HDV in Italy by Therapies, in USD Million (2017-2030)
Figure 67: Market Size of HDV in Spain by therapies, in USD Million (2017-2030)
Figure 68: Market Size of HDV in the United Kingdom by Therapies, in USD Million (2017-2030)
Figure 69: Market Size of HDV in Japan by Therapy, in USD Million (2017-2030)
Figure 70: Market Drivers of HDV
Figure 71: Market Barriers of HDV
Note: Product cover images may vary from those shown
  • MYR Pharmaceuticals/Hepatera
  • Eiger Biopharmaceuticals
  • Janssen Biopharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll